Harmony & Health: Feasibility of a Movement Intervention to Improve Psychosocial Wellbeing in Black Adults in Northeast Texas
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05761964
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
3D Printed Breast Models in the Surgical Management of Breast Cancer
Not Applicable
Recruiting
- Conditions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT05755984
Vapocoolant Analgesia for Breast Lymphoscintigraphy
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05744557
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05743842
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
Recruiting
- Conditions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT05733091
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05722327
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05717400
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05715216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Randomized Trial Comparing a Ventilatory Strategy to Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA Vs. LADS Trial)
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05714033
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05709782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath